Accueil>>MRS2179 tetrasodium hydrate

MRS2179 tetrasodium hydrate

Catalog No.GC61090

L'hydrate de tétrasodium MRS2179 est un antagoniste compétitif du récepteur P2Y1, avec un Kb de 102 nM et un pA2 de 6,99 pour le récepteur P2Y1 de dinde.

Products are for research use only. Not for human use. We do not sell to patients.

MRS2179 tetrasodium hydrate Chemical Structure

Taille Prix Stock Qté
1mg
198,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors[1][2]. MRS2179 tetrasodium hydrate inhibits platelet aggregation[3].

MRS2179 tetrasodium hydrate (50 mg/kg; i.p.) prolongs the bleeding time[3]. Animal Model: CL57BLr6 mice[3]

[1]. Nandanan E, et al. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem. 2000;43(5):829-842. [2]. von KÜgelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther. 2006;110(3):415-432. [3]. Baurand A, Raboisson P, Freund M, et al. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol. 2001;412(3):213-221.

Avis

Review for MRS2179 tetrasodium hydrate

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MRS2179 tetrasodium hydrate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.